8月19日，莫德纳股价在黑色素瘤疫苗3期试验结果积极的推动下飙升约177%Rothschild & Co以估值过高为由下调MRNA评级，目标价为$81引述“反应过度”— Simon Baker“估值明显过高”— Simon Baker来源Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. saysCNBCModerna Doubled in a Day. What Happens Now Is the Real Question.MMarketspectator
